EP0305194A2 - Veterinary composition - Google Patents
Veterinary composition Download PDFInfo
- Publication number
- EP0305194A2 EP0305194A2 EP88307919A EP88307919A EP0305194A2 EP 0305194 A2 EP0305194 A2 EP 0305194A2 EP 88307919 A EP88307919 A EP 88307919A EP 88307919 A EP88307919 A EP 88307919A EP 0305194 A2 EP0305194 A2 EP 0305194A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- active agent
- biologically active
- melatonin
- veterinary composition
- complementary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Definitions
- This invention relates to a method of regulating the reproductive functions of animals, particularly domesticated ruminants, and to veterinary compositions for use in such a method.
- a veterinary composition including an effective amount of
- the primary biologically active agent of the veterinary composition according to this aspect of the present invention may be selected from Melatonin or related or derived chemicals of the indole class. While the present invention describes the use of Melatonin per se, it has been established in the prior art that certain other related or derived molecules may exert a similar biological effect. Thus Kennaway et al. (1986) have demonstrated that certain classes of Melatonin derivative or analogue (notably those halogenated at the indol-6 position, those carrying a saturated bond at the indol-2,3 position, and those arising from cleavage of the indolyl ring) have a similar, although lesser, effect on serum prolactin levels when administered to sheep, compared to Melatonin.
- the active agent of the coated veterinary implant according to this aspect of the present invention may be selected from MELATONIN (N-acetyl 5-methoxy tryptamine) MELATONIN analogues substituted at the amino nitrogen, e.g.: N-propionyl/N-butyryl MELATONIN analogues substituted at the 5- position, e.g.: 5-ethoxy (i.e. N-acetyl O-ethyl serotonin) 5-propoxy (i.e.
- MELATONIN analogues substituted at the 6- position e.g.: Halo-substituted: 6-fluoro/6-bromo/6-chloro/6-iodo Hydroxy- substituted Suphatoxy- substituted Alkyl- substituted: 6-methyl/6-ethyl/6-isopropyl etc. Alkoxy- substituted, e.g. 6-methoxy Silylated, e.g.
- 6-(t-butyl)dimethylsiloxy SATURATED MELATONIN DERIVATIVES such as (2,3-dihydro)melatonin and 6-chloro-(2,3-dihydro)melatonin (together with all the 5-, 6- and N- substituted saturated derivatives thereof as described above)
- RING-CLEAVED MELATONIN derivatives including all the 5- 6- and N- substituted derivatives thereof as described above, and similarly, saturated derivatives thereof
- N-acetyl 5-hydroxy kynurenamine N-acetyl 5-methoxy kynurenamine RELATED INDOL (SEROTONIN) derivatives such as N-acetyl serotonin N,O-diacetyl serotonin N-acetyl tryptamine Serotonin 5-methoxy tryptophol 5-methoxy tryptamine OTHER DERIVATIVES and RELATIVES of MELATONIN, such as N-alkyl and/or
- season physiological responses as used herein in the description and claims we mean changes in the physiology of the animal to be treated which are affected, under natural conditions, by season. Such aspects include changes to the growth and colour or quality of pelage, and development of horn or antler, appetite, reproductive activity and the like.
- the amount of melatonin or related chemicals of the indole class as defined above in the formulation may be sufficient to provide for an elevation of the circulating blood concentration of melatonin or equivalent active material to greater than the normal daytime level in an untreated animal for a period of up to several weeks.
- melatonin analogues may show a relationship between administered dose, blood level and biological effect which is different from that seen with melatonin itself.
- the primary biologically active agent may contribute approximately 2.5 to 98% by weight based on the total weight of the veterinary composition, depending on the species and breed to be treated, the type of primary active, the type of excipient and the secondary active or actives included in the composition.
- the active agent may be present in amounts of from approximately 75 to 98% by weight based on the total weight of the veterinary composition.
- the at least one complementary biologically active agent of the veterinary composition according to this aspect of the present invention may be selected from any one or more of the following classes
- agents falling within each class are as follows:
- Progesterone or other progestagens which may be used to control the timing of oestrus and/or to permit the expression of oestrus at the first ovulation of the season or induced season.
- Prostaglandins particularly those of the E and F class, and particularly Prostaglandin PGF2 and its analogues in all their forms.
- - Conjugated steriods which are themselves antigenic or which are antigenic in combination with adjuvants or enhancers of immune responses - e.g.: andostenedione conjugate (Fecundin), oestrone conjugate, oestradiol-17-beta conjugates or mixtures thereof.
- gonadotrophic substances include: - Pregnant Mare Serum Gonadotrophin (PMSG) -Follicle Stimulating Hormone (FSH) including, but not exclusively those of equine, ovine, bovine and porcine origin.
- - Luteinizing hormone and its biologically active analogues - Luteinizing hormone and its biologically active analogues.
- Inhibin whether of testicular or ovarian origin, and whether homologous or heterologous, or whether obtained by genetic engineering, or by purification from inhibin-rich, naturally-occurring tissues or fluids.
- - Immunizing forms of Inhibin such as chemically altered Inhibin, heterologous Inhibin, or Inhibin conjugated with other substances.
- GnRH Gonadotropin Releasing Hormone
- LHRH Luteinizing Hormone Releasing Hormone
- Prolactin or prolactin analogues, or substances other than the primary active which affect prolactin levels e.g. bromocriptine
- hypothalamo-pituitary axis whether natural or synthetic e.g.: those produced by goat bucks, deer stags, boars and rams during and aroung the natural or induced breeding season.
- Thyroid hormones such as T4, T3 and Thyrotropins, whether natural or synthetic.
- the at least one complementary biologically active agent is selected from progestagens, prostaglandins, conjugated steroids, gonadotrophins or mixtures thereof.
- the at least one complementary biologically active agent may be administered in combination with the primary biologically active agent.
- the secondary biologically active agent may be adminstered before or after the administration of the primary agent.
- the veterinarily acceptable carrier or excipient may include non-toxic oils of vegetable or mineral origin, polymers, alcohols and other diluents.
- Useful non-toxic carriers may include peanut oil, hydrogenated vegetable oil, glycols, ethanol, isopropanol, polyols such as glycerol, sorbitol and propylene glycol and ketones such as acetone.
- the veterinarily acceptable carrier or excipient may include a compressible pharmaceutical vehicle selected to control the release rate of the active agent.
- the carrier or excipient may be present in amounts of approximately 1 to 95% by weight based on the total weight of the veterinary composition.
- Such a vehicle may be a high molecular weight form of ethyl cellulose.
- the form of ethyl cellulose may be chosen from the range of ethoxylated cellulose derivatives sold under the trade designation "Ethocel” and available from the Dow Chemical Company. Ethocel Standard and Ethocel Medium, both of viscosity grades between 7 cP and 100 cP, are preferred.
- the veterinary carrier or excipient may include an acid salt.
- the acid salt may be a phosphate salt.
- the vehicle may be an alkaline earth metal salt.
- a calcium phosphate is preferred.
- a hydrated acid salt may be used.
- a dibasic calcium phosphate dihydrate is preferred.
- the acid salt may be a calcium phosphate of the type sold under the trade designation "Encompress" and available from Edward Mendell Co. Inc., New York, United States of America.
- Such agents may include colouring agents, flavourant, fillers, binders, surfactants and the like.
- the veterinary composition may preferably take the form of a veterinary implant.
- a veterinary implant Such implants have been described in European Patent Publications Nos 0169856 and 0246910, the entire disclosure of each of which is incorporated herein by reference. These implants comprise melatonin, a related indole or derivative thereof as the active ingredient and additionally a veterinally acceptable carrier or excipient. They may have a coating which is formed from a physiologically compatible polymeric coating composition.
- the secondary biologically active agent may be incorporated in the veterinary implant, or may be administered separately.
- the implants may be individually or severally loaded into a separate chamber of a plastic cartridge.
- the plastic cartridges may be placed into a "gun” and the implant delivered subcutaneously through a large bore needle.
- subcutaneous implantation is our preferred route for administering these implants, they may be effective when administered orally, vaginally, intraperitoneally (I.P.), percutaneously or intramuscularly (I.M.).
- I.P. intraperitoneally
- I.M. intramuscularly
- the IM or I.P routes may be used in particular in fur-bearing animals, such as mink and angora rabbits.
- a method of regulating the seasonal breeding activity and/or related physiological responses in animals which method includes administering to an animal to be treated an effective amount of
- the at least one complementary biologically active agent is selected from any one of the following classes;
- the at least one complementary biologically active agent is selected from progestagens, prostaglandins, conjugated steriods, Gonadotrophins or mixtures thereof.
- a method of regulating the seasonal breeding activity and/or related physiological responses of animals which method includes administering to an animal to be treated an effective amount of a veterinary composition including an effective amount
- the primary biologically active agent may be provided in the form of a veterinary implant as described above.
- the at least one complementary biologically active agent may be selected from any one of the following classes;
- the at least one complementary biologically active agent is selected from progestagens, prostaglandins, conjugated steroids, Gonadotrophins or mixtures thereof.
- the at least one complementary biologically active ingredient may also be supplied in the same or a different implant.
- the at least one complementary biologically active agent may be in an injectable form, or in the form of an intrauterine or intravaginal device, for example a sponge.
- progesterone may be provided in a progesterone-releasing controlled intravaginal delayed release device CIDR.
- veterinary composition may further be applied to the regulation of seasonal breeding or other physiological events in birds, such as turkeys, geese, and fowls and in fish including sturgeon, trout, salmon and eels where applications may include alterations to the time of spawning or of the smolt process.
- the method of regulating the reproductive functions in animals may be such as to advance or delay the onset of oestrus or breeding activity, to induce or delay the onset of ovulation or sperm production, or to increase the rate of ovulation or sperm production.
- the duration of the animal's breeding season may be altered. Some or all of these effects may be obtained in just the season of treatment or may continue for an extensive period, e.g. two to four years, or throughout the reproductive life of the animal.
- the animal to be treated may be a mature animal.
- the seasonal breeding activity may be modified by accelerating the onset of oestrus or the breeding cycle.
- the animal to be treated may be a pre-pubescent animal and the seasonal breeding activity is modified by delaying the onset of puberty and thus the onset of the breeding season is altered over a number of years.
- the animal to be treated will be a female.
- the male of the species may be treated. This is preferably for deer and goats and to a lesser extent, sheep.
- the composition may be administered to both entire and castrate male and female animals.
- the reproductive functions of female animals may be regulated by increasing the rate of ovulation in such treated animals.
- this invention provides a method of regulating the physiological characteristics of animals which method includes inserting a coated veterinary implant of the type described above into an animal to be treated.
- the induction of an earlier onset to the breeding season has a number of advantages including allowing earlier joining for lamb drop in more favourable weather, longer growth periods for lambs and minimizing potential labour clashes for management of lambing and for marking with that required for other enterprises on the farm such as harvesting the crops.
- Melatonin treatment permits a defined joining time since treated ewes reliably respond to "ram effect” and therefore mate and concieve at about 3 to 4 weeks after introduction of rams. Although melatonin implants are typically used in sheep in conjunction with the "ram effect” they will induce changes in reproductive activity without the additional use of rams.
- Melatonin treatment may shorten the conception period so that lambing period will be condensed (this allows for an even crop of lambs and maximization of labour inputs over a short lambing period).
- Certain other physical characteristics of animals may be regulated in a similar way by means of the coated sustained-release melatonin implant described herein.
- the physiological characteristics which may be regulated are those usually associated with reproductive activity or seasonal changes, and include changes in the thickness or the colour of the animal's coat, pelt or fur, and the development of horn or antler.
- compositions or treatments which combine melatonin with one or more secondary biologically active agents have been found to have greater, or more beneficial, activity than compositions or treatments which involve either agent alone.
- treatment groups 1 and 2 were implanted with melatonin on 12th December and 23rd December respectively. Melatonin on 12th December and 23rd December respectively. Melatonin treated ewes were grazed separately from untreated ewes.
- Treatment groups 1 and 3 had CIDR's inserted to each ewe on 7th January and removed on 19th January after a period of at least 5 weeks isolation from rams.
- Rams were fitted with a harness containing a wax marking crayon which marked ewes on the day of mating.
- Table 1 Lambing results Ewes lambing/ewes present Ewes lambing multiple/ewe lambing % Lambs born/ewes mated Group Treatment BxR R BxR R BxR R 1 Melatonin CIDR 67 76 57 24 1.14 0.94 2 Melatonin only 84 81 19 32 1.00 1.06 3 CIDR only 62 74 23 8 0.73 0.79 4 Control 75 57 7 6 0.80 0.56
- the mean interval from ram introduction to first observed oestrus in the B x P ewes was 8, 25, 16 and 26 days respectively for the four treatments, and in the Romney ewes the interval was 16, 26, 27 and 30 for groups 1, 2, 3 and 4 respectively.
- the aim of this trial was to evaluate the efficacy of melatonin feeding and melatonin implants to advance seasonal reproductive activity.
- Ovulation was synchronised in MF and MI groups by either intravaginal progesterone (CIDR) only (inserted 17th February and removed 4th March) or by two prostaglandin F2 (PG) injections (250 ug closprostenol, Estrumate, ICI, on 21st February and 3rd March) and in the control group by CIDR only.
- CIDR intravaginal progesterone
- PG prostaglandin F2
- the overall treatment protocol was as follows: Day 0 10-4-88 Implant with Regulin® melatonin implant Day 28 07-5-88 Insert progesterone sponges intravaginally Day 38 17-5-88 Introduce teaser rams Day 41 20-5-88 Remove sponges, inject PM5G (0600 h) Day 43 22-5-88 Inseminate at 50 and 60 h after PMSG injection Day 57 06-6-88 Introductions of rams with markers to look for "returns", continued to Day 64 Day 92 11-7-88 Ultrasound pregnancy check
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
- (I) a primary biologically active agent selected from melatonin or related chemicals of the indole class or mixtures thereof;
- (II) at least one complementary biological active agent; eg oestrus synchronizing agents; pheromones; or substances involved with brain function, including neurotransmitters; and
- (III) a veterinarily acceptable carrier or excipient.
Description
- This invention relates to a method of regulating the reproductive functions of animals, particularly domesticated ruminants, and to veterinary compositions for use in such a method.
- In our earlier Australian Patent Application No. 78305/81 there is described a method of artificially mimicking changing photoperiod, thereby changing the breeding activity of sheep, goats, deer and other seasonally breeding animals, by the judicious feeding of Melatonin or similarly effective related chemicals. In subsequent applications 38111/85 and 72915/87, (European Patent Publications Nos 0169856 and 0246910) we describe improved methods of administering melatonin to achieve this same effect.
- The role of seasonal environmental factors, in particular the photoperiod, in determining the breeding period of sheep is well established. Under natural conditions the changing of day length such as when summer leads to autumn is the main trigger to the reproductive system to commence ovarian cyclicity. Our previous applications show that melatonin treatment can mimick the effects of short day length on ewes, such that the breeding season is advanced and basal prolactin levels are depressed.
- However whilst these prior art methods have proved to be effective, more extensive modification of breeding activity and/or other physiological effects, would be most desirable.
- It is accordingly an object of the present invention to overcome, or at least alleviate, one or more of the difficulties related to the prior art.
- Accordingly, in a first aspect, there is provided a veterinary composition including an effective amount of
- (i) a primary biologically active agent selected from melatonin or related chemicals of the indole class, as hereinafter defined, or mixtures thereof,
- (ii) at least one complementary biologically active agent,
- (iii) a veterinarily acceptable carrier or excipient,
- We have discovered that other biologically active agents in conjunction with melatonin may have further beneficial effects, beyond the effect of either active alone.
- The primary biologically active agent of the veterinary composition according to this aspect of the present invention may be selected from Melatonin or related or derived chemicals of the indole class. While the present invention describes the use of Melatonin per se, it has been established in the prior art that certain other related or derived molecules may exert a similar biological effect. Thus Kennaway et al. (1986) have demonstrated that certain classes of Melatonin derivative or analogue (notably those halogenated at the indol-6 position, those carrying a saturated bond at the indol-2,3 position, and those arising from cleavage of the indolyl ring) have a similar, although lesser, effect on serum prolactin levels when administered to sheep, compared to Melatonin. (Kennaway, D.J., P. Royles, E.A. Dunstan and H.M. Hugel, 1986. Prolactin Response in Border Leicester x Merino Ewes to Administration of Melatonin, Melatonin Analogues, a Melatonin Metabolite and 6-Methoxybenzoxazolinone. Australian Journal of Biological Sciences, 39:427-433). Similarly, Frohn et al (1980) using a biological assay highly specific for Melatonin-like activity, have established the biological activity of a variety of analogues, derivatives, and related indole compounds, relative to Melatonin itself. (Frohn, M.A., C.J. Seaborn, D.W. Johnson, G. Phillipou, R.F. Seamark and C.D. Matthews, 1980. Structure-activity Relationship of Melatonin Analogues. Life Sciences, 27:2043-2046). Accordingly, the active agent of the coated veterinary implant according to this aspect of the present invention may be selected from
MELATONIN (N-acetyl 5-methoxy tryptamine)
MELATONIN analogues substituted at the amino nitrogen, e.g.:
N-propionyl/N-butyryl
MELATONIN analogues substituted at the 5- position,
e.g.: 5-ethoxy (i.e. N-acetyl O-ethyl serotonin)
5-propoxy (i.e. N-acetyl O-propyl serotonin)
MELATONIN analogues substituted at the 6- position,
e.g.: Halo-substituted: 6-fluoro/6-bromo/6-chloro/6-iodo
Hydroxy- substituted
Suphatoxy- substituted
Alkyl- substituted: 6-methyl/6-ethyl/6-isopropyl etc.
Alkoxy- substituted, e.g. 6-methoxy
Silylated, e.g. 6-(t-butyl)dimethylsiloxy
SATURATED MELATONIN DERIVATIVES, such as (2,3-dihydro)melatonin and 6-chloro-(2,3-dihydro)melatonin (together with all the 5-, 6- and N- substituted saturated derivatives thereof as described above)
RING-CLEAVED MELATONIN derivatives (including all the 5- 6- and N- substituted derivatives thereof as described above, and similarly, saturated derivatives thereof), such as
N-acetyl 5-hydroxy kynurenamine
N-acetyl 5-methoxy kynurenamine
RELATED INDOL (SEROTONIN) derivatives, such as
N-acetyl serotonin
N,O-diacetyl serotonin
N-acetyl tryptamine
Serotonin
5-methoxy tryptophol
5-methoxy tryptamine
OTHER DERIVATIVES and RELATIVES of MELATONIN, such as
N-alkyl and/or N,N-dialkyl analogues of tryptamine, serotonin and melatonin
N-aryl and/or N,N-diaryl analogues of tryptamine, serotonin and melatonin
Similarly, mixed N-alkyl, N-aryl derivatives 5-substituted derivatives of tryptamine, Ureido- analogues of tryptamine and serotonin; or mixtures thereof. - By "seasonal physiological responses" as used herein in the description and claims we mean changes in the physiology of the animal to be treated which are affected, under natural conditions, by season. Such aspects include changes to the growth and colour or quality of pelage, and development of horn or antler, appetite, reproductive activity and the like.
- The amount of melatonin or related chemicals of the indole class as defined above in the formulation may be sufficient to provide for an elevation of the circulating blood concentration of melatonin or equivalent active material to greater than the normal daytime level in an untreated animal for a period of up to several weeks.
- It is recognised that melatonin analogues may show a relationship between administered dose, blood level and biological effect which is different from that seen with melatonin itself. Thus the primary biologically active agent may contribute approximately 2.5 to 98% by weight based on the total weight of the veterinary composition, depending on the species and breed to be treated, the type of primary active, the type of excipient and the secondary active or actives included in the composition.
- For animals such as sheep, deer and the like the active agent may be present in amounts of from approximately 75 to 98% by weight based on the total weight of the veterinary composition.
- For animals such as mink and fox amounts of active agent of from approximately 25 to 75% by weight may be used.
- The at least one complementary biologically active agent of the veterinary composition according to this aspect of the present invention may be selected from any one or more of the following classes
- (A) oestrus synchronizing agents;
- (B) other agents which directly or indirectly increase ovarian function;
- (C) pheromones or pheromone analogues;
- (D) substances involved with thyroid function; and
- (E) substances involved with brain function, including neurotransmitters;
or mixtures thereof. - Examples of agents falling within each class are as follows:
- - Progesterone or other progestagens which may be used to control the timing of oestrus and/or to permit the expression of oestrus at the first ovulation of the season or induced season.
- Other steriods in general - natural or synthetic.
- Prostaglandins - particularly those of the E and F class, and particularly Prostaglandin PGF2 and its analogues in all their forms.
- - Conjugated steriods which are themselves antigenic or which are antigenic in combination with adjuvants or enhancers of immune responses - e.g.: andostenedione conjugate (Fecundin), oestrone conjugate, oestradiol-17-beta conjugates or mixtures thereof.
- Gonadotrophin or mixtures or preparations with gonadotropin activity whether homologous or heterologous to the species in which the veterinary composition is to be used.
Examples of such gonadotrophic substances include:
- Pregnant Mare Serum Gonadotrophin (PMSG) -Follicle Stimulating Hormone (FSH) including, but not exclusively those of equine, ovine, bovine and porcine origin. - Luteinizing hormone and its biologically active analogues. - Inhibin, whether of testicular or ovarian origin, and whether homologous or heterologous, or whether obtained by genetic engineering, or by purification from inhibin-rich, naturally-occurring tissues or fluids.
- Immunizing forms of Inhibin such as chemically altered Inhibin, heterologous Inhibin, or Inhibin conjugated with other substances.
- Releasing factors in general, and in particular those associated with the control of gonadotrophin secretion, such as Gonadotropin Releasing Hormone (GnRH) also known as Luteinizing Hormone Releasing Hormone (LHRH) or its natural or synthetic analogues including those of agonistic or antogonistic action.
- Prolactin or prolactin analogues, or substances other than the primary active which affect prolactin levels (e.g. bromocriptine)
- - Olfactory stimuli which are known to affect the activity of the hypothalamo-pituitary axis (phermones), whether natural or synthetic e.g.: those produced by goat bucks, deer stags, boars and rams during and aroung the natural or induced breeding season.
- - Thyroid hormones, such as T4, T3 and Thyrotropins, whether natural or synthetic.
- - Neutotransmitter substances.
- More preferably the at least one complementary biologically active agent is selected from progestagens, prostaglandins, conjugated steroids, gonadotrophins or mixtures thereof.
- The at least one complementary biologically active agent may be administered in combination with the primary biologically active agent. Alternatively the secondary biologically active agent may be adminstered before or after the administration of the primary agent.
- The veterinarily acceptable carrier or excipient may include non-toxic oils of vegetable or mineral origin, polymers, alcohols and other diluents. Useful non-toxic carriers may include peanut oil, hydrogenated vegetable oil, glycols, ethanol, isopropanol, polyols such as glycerol, sorbitol and propylene glycol and ketones such as acetone. The veterinarily acceptable carrier or excipient may include a compressible pharmaceutical vehicle selected to control the release rate of the active agent. The carrier or excipient may be present in amounts of approximately 1 to 95% by weight based on the total weight of the veterinary composition.
- Such a vehicle may be a high molecular weight form of ethyl cellulose. The form of ethyl cellulose may be chosen from the range of ethoxylated cellulose derivatives sold under the trade designation "Ethocel" and available from the Dow Chemical Company. Ethocel Standard and Ethocel Medium, both of viscosity grades between 7 cP and 100 cP, are preferred.
- Alternatively, or in addition, the veterinary carrier or excipient may include an acid salt. The acid salt may be a phosphate salt. The vehicle may be an alkaline earth metal salt. A calcium phosphate is preferred. A hydrated acid salt may be used. A dibasic calcium phosphate dihydrate is preferred. The acid salt may be a calcium phosphate of the type sold under the trade designation "Encompress" and available from Edward Mendell Co. Inc., New York, United States of America.
- Other compounding agent may also be included. Such agents may include colouring agents, flavourant, fillers, binders, surfactants and the like.
- The veterinary composition may preferably take the form of a veterinary implant. Such implants have been described in European Patent Publications Nos 0169856 and 0246910, the entire disclosure of each of which is incorporated herein by reference. These implants comprise melatonin, a related indole or derivative thereof as the active ingredient and additionally a veterinally acceptable carrier or excipient. They may have a coating which is formed from a physiologically compatible polymeric coating composition.
- The secondary biologically active agent may be incorporated in the veterinary implant, or may be administered separately.
- The implants may be individually or severally loaded into a separate chamber of a plastic cartridge. The plastic cartridges may be placed into a "gun" and the implant delivered subcutaneously through a large bore needle.
- Although subcutaneous implantation is our preferred route for administering these implants, they may be effective when administered orally, vaginally, intraperitoneally (I.P.), percutaneously or intramuscularly (I.M.). The IM or I.P routes may be used in particular in fur-bearing animals, such as mink and angora rabbits.
- In a further aspect of the present invention there is provided a method of regulating the seasonal breeding activity and/or related physiological responses in animals which method includes administering to an animal to be treated an effective amount of
- (I) a primary biologically active agent selected from melatonin or related chemicals in the indole class, as hereinbefore defined, or mixtures therof; and
- (II) at least one complementary biologically active agent.
- Preferably the at least one complementary biologically active agent is selected from any one of the following classes;
- (A) oestrus synchronizing agents;
- (B) other agents which directly or indirectly increase ovarian function;
- (C) pheromones or pheromone analogues;
- (D) substances involved with thyroid function; and
- (E) substances involved with brain function, including neurotransmitters.
- More preferably the at least one complementary biologically active agent is selected from progestagens, prostaglandins, conjugated steriods, Gonadotrophins or mixtures thereof.
- In a preferred form there is provided a method of regulating the seasonal breeding activity and/or related physiological responses of animals which method includes administering to an animal to be treated an effective amount of a veterinary composition including an effective amount
- (I) a primary biologically active agent selected from melatonin or related chemicals of the indole class, as hereinbefore defined, or mixtures thereof,
- (II) at least one complementary biologically active agent,
- (III) a veterinarily acceptable carrier or excipient.
- In a still further aspect of the present invention there is provided a kit of parts including
- (i) a primary biologically active agent selected from melatonin or related chemicals of the indole class, as hereinbefore defined, or mixtures thereof, in a suitable container or delivery vehicle, and
- (ii) at least one complementary biologically active agent in a suitable container or delivery vehicle.
- The primary biologically active agent may be provided in the form of a veterinary implant as described above.
- The at least one complementary biologically active agent may be selected from any one of the following classes;
- (A) oestrus synchronizing agents;
- (B) other agents which directly or indirectly increase ovarian function;
- (C) pheromones or pheromone analogues;
- (D) substances involved with thyroid function; and
- (E) substances involved with brain function, including neurotransmitters.
- More preferably, the at least one complementary biologically active agent is selected from progestagens, prostaglandins, conjugated steroids, Gonadotrophins or mixtures thereof. The at least one complementary biologically active ingredient may also be supplied in the same or a different implant. The at least one complementary biologically active agent may be in an injectable form, or in the form of an intrauterine or intravaginal device, for example a sponge.
- Where progesterone is used this may be provided in a progesterone-releasing controlled intravaginal delayed release device CIDR.
- In the following description, reference will be made to the administration of the veterinary composition to sheep. It should be understood, however, that such animals are mentioned for illustrative purposes only and the veterinary composition is applicable to animals generally, including sheep, goats, horses, deer, pigs, ferrets, mink, fox. The veterinary composition may further be applied to the regulation of seasonal breeding or other physiological events in birds, such as turkeys, geese, and fowls and in fish including sturgeon, trout, salmon and eels where applications may include alterations to the time of spawning or of the smolt process.
- The method of regulating the reproductive functions in animals may be such as to advance or delay the onset of oestrus or breeding activity, to induce or delay the onset of ovulation or sperm production, or to increase the rate of ovulation or sperm production. In advancing or delaying the onset of ovulation or sperm production, the duration of the animal's breeding season may be altered. Some or all of these effects may be obtained in just the season of treatment or may continue for an extensive period, e.g. two to four years, or throughout the reproductive life of the animal.
- The animal to be treated may be a mature animal. The seasonal breeding activity may be modified by accelerating the onset of oestrus or the breeding cycle.
- The animal to be treated may be a pre-pubescent animal and the seasonal breeding activity is modified by delaying the onset of puberty and thus the onset of the breeding season is altered over a number of years.
- In general, the animal to be treated will be a female. However, alternatively or in addition the male of the species may be treated. This is preferably for deer and goats and to a lesser extent, sheep. Where changes in pelage (fur/wool/coat/pelt production etc.) are sought, the composition may be administered to both entire and castrate male and female animals.
- In a further preferred aspect of this invention, the reproductive functions of female animals may be regulated by increasing the rate of ovulation in such treated animals.
- In a further related aspect, this invention provides a method of regulating the physiological characteristics of animals which method includes inserting a coated veterinary implant of the type described above into an animal to be treated.
- With respect to sheep, for example, the induction of an earlier onset to the breeding season has a number of advantages including allowing earlier joining for lamb drop in more favourable weather, longer growth periods for lambs and minimizing potential labour clashes for management of lambing and for marking with that required for other enterprises on the farm such as harvesting the crops.
- Melatonin treatment permits a defined joining time since treated ewes reliably respond to "ram effect" and therefore mate and concieve at about 3 to 4 weeks after introduction of rams. Although melatonin implants are typically used in sheep in conjunction with the "ram effect" they will induce changes in reproductive activity without the additional use of rams.
- Melatonin treatment may shorten the conception period so that lambing period will be condensed (this allows for an even crop of lambs and maximization of labour inputs over a short lambing period).
- Melatonin treatment induces the normal peak seasonal ovulation rates to occur early in the season. Fecundity (number of lambs/ewe joined) is therefore increased by 14 to 30%. This is due mostly to an increased occurrence of twins or triplets and to a decrease in the proportion which are not pregnant.
- Certain other physical characteristics of animals may be regulated in a similar way by means of the coated sustained-release melatonin implant described herein. The physiological characteristics which may be regulated are those usually associated with reproductive activity or seasonal changes, and include changes in the thickness or the colour of the animal's coat, pelt or fur, and the development of horn or antler.
- We have now discovered unexpectedly that supplementary treatment with melatonin as described herein may enhance the effect of various other treatments designed to manipulate various aspects of the reproductive and/or physiological responses of target animals. Thus, in practice, compositions or treatments which combine melatonin with one or more secondary biologically active agents have been found to have greater, or more beneficial, activity than compositions or treatments which involve either agent alone.
- We have found that combination of melatonin treatment with oestrus synchronising treatment (progesterone priming) of ewes leads to a significant shortening of the mean time to conception, compared to treatment with progesterone alone (see example 1). A corresponding phenomenon has been observed in deer (example 3). Similarly, supplementary melatonin treatment has been found to overcome some of the limitations of steroid immunization, in particular preventing the delay in mating pattern seen with immunized ewes, and reducing the occurrence of barren ewes, typical of steroid immunized animals (see example 2). In addition, supplementary melatonin treatment has been found to further enhance the combined effect of progestagen oestrus synchronization and gonadotrophic stimulation on conception rates in artificial insemination (example 4).
- The present invention will now be more fully described with reference to the accompanying examples. It should be understood, however, that the examples are illustrative only and should not be taken in any way as a restriction on the generality of the invention described above.
- The effect of Regulin® melatonin implants and type C CIDR's (progesterone-releasing intravaginal devices) on the early breeding of 84 Booroola Merino X perendale (B x P) and 142 Waihorn Romney (R) ewes were compared in four treatment groups:
- Group (1) melatonin plus CIDR;
- Group (2) melatonine only
- Group (3) CIDR only;
- Group (4) control.
- In this example treatment groups 1 and 2 were implanted with melatonin on 12th December and 23rd December respectively. Melatonin on 12th December and 23rd December respectively. Melatonin treated ewes were grazed separately from untreated ewes. Treatment groups 1 and 3 had CIDR's inserted to each ewe on 7th January and removed on 19th January after a period of at least 5 weeks isolation from rams. Rams were fitted with a harness containing a wax marking crayon which marked ewes on the day of mating. The ewes were joined in four mating groups, Romney ewes were mated to Booroola Merino (FF genotype) x Romney rams in melatonin treated and untreated groups, and Booroola x Perendale ewes were mated to Booroola (++ genotype) x Romney rams in treated and untreated groups.
- The results are summarized in Table 1.
Table 1 Lambing results Ewes lambing/ewes present Ewes lambing multiple/ewe lambing % Lambs born/ewes mated Group Treatment BxR R BxR R BxR R 1 Melatonin CIDR 67 76 57 24 1.14 0.94 2 Melatonin only 84 81 19 32 1.00 1.06 3 CIDR only 62 74 23 8 0.73 0.79 4 Control 75 57 7 6 0.80 0.56 - The mean interval from ram introduction to first observed oestrus in the B x P ewes was 8, 25, 16 and 26 days respectively for the four treatments, and in the Romney ewes the interval was 16, 26, 27 and 30 for groups 1, 2, 3 and 4 respectively.
- These results indicate a synergistic effect of the combined treatments on the onset of first oestrus in the Merino x Romney breed. Similarly there was a synergistic effect of the combined treatment in % of ewes lambing multiples in B x P ewes (Table 1). Synergistic effect in lambing percentages was also seen in ewes of the Boorolla x Romney and Romney breeds when progesterone intravaginal possaries and melatonin implants were used together. In the BxR ewes the combined treatment resulted in at least 0.41 additional lambs per ewe treated compared with just the progesterone alone, and in the Romney ewes this increase was 0.15 additional lambs in the combined treatment compared with the use of progesterone alone.
- Breed: Mature Border Leicester x Merino ewes mated to Dorset rams
Joining Date: 18th December, 1987, about three months prior to the natural Autumn seasonal peak in reproductive performance.
Location: Kybybolite, South Australia
Independent Supervisor: Eugene Dunstan - Sheep industry specialist of the South Australia Government Department of Agriculture.
- The treatment groups were as summarised in the following table:
Treatment compared Ewes observed Compared: Group 1 - Control n = 81 Group 2 - Regulin® melatonin implant n = 78 Group 3 - Recundin® (androstendione immunization) n = 81 Group 4 - Regulin + Fecundin n = 83 - The results are summarized in Table 2. While the combined treatement in this particular example had only a marginal effect on the delay in mating pattern, it had a significant improving effect on the conception rate, as well as reducing the number of barren ewes.
- There are significant advantages to be gained by advancing the calving season of red deer hinds from early summer to spring, particularly that of improved pasture utilisation.
- The aim of this trial was to evaluate the efficacy of melatonin feeding and melatonin implants to advance seasonal reproductive activity.
- From 10th December until 6th March, at 1500 h each day, 30 hinds were fed 5 mg/head/day melatonin incorporated in a ration of deer nuts (MF). During the same period 16 hinds were each given two subcutaneous constant melatonin releasing implants (Genelink, Australia) replaced at approximately 28 day intervals (MI). A further six hinds remained untreated (C).
- Ovulation was synchronised in MF and MI groups by either intravaginal progesterone (CIDR) only (inserted 17th February and removed 4th March) or by two prostaglandin F2 (PG) injections (250 ug closprostenol, Estrumate, ICI, on 21st February and 3rd March) and in the control group by CIDR only.
- Evidence of a previous ovulation, determined by laparoscopy on 12th March, was recorded in 9/20 MF, 12/16 MI and 0/6 C hinds. Nine of the MF hinds which did not ovulate however, did not consistently eat the treated ration. of the MF hinds which ate their ration, 4/5 CIDR and 5/6 PG treated had a curpus luteum. Of the MI hinds 7/8 CIDR and 5/8 PG treated hinds had a corpus luteum.
TABLE 2 KYBYBOLITE, SOUTH AUSTRALIA - BLxM Joined 18.01.87 FETUSES FETUSES/CONC. RATE % MATING EWE PREGNANT MEAN MEAN MATING DAY CONC. DAY GROUP n 0 1 2 3 0 1 2 3 CONTROL 81 4 33 41 3 1.530A 1.610X 1 80 9 - 20.48 21.54 % 4.94 40.7 50.6 3.7 1.27 98.8 11.1 - REGULIN 78 4 20 52 2 1.666AB 1.756XX 2 76 6 1 19.82 20.12 % 5.1 25.6 66.7 2.56 2.56 97.4 7.7 1.28 FECUNDIN 81 13 19 40 9 1.555B 1.852X 5 76 11 - 24.52 25.89 % 16.1 23.5 49.4 11.1 6.2 93.8 13.6 - REGULIN & FECUNDIN 83 3 21 37 21 1.952C 2.025X 2 81 13 1 23.03 25.70 3.6 25.3 44.5 25.3 2.4 97.6 15.7 1.2 VALUES WITH DIFFERENT SUPERSCRIPTS DIFFER SIGNIFICANTLY, P<0.05 - This trial has demonstrated that both daily melatonin feeding and melatonin implants are capable of advancing the breeding season of yearling red deer hinds, with both methods appearing reliable once the problem of feed acceptance is overcome. The results from prostaglandin treatment suggests that those animals were cycling prior to the time of synchronisation, and that the breeding season could be advanced still further using the melatoniin treatments described here.
- Breed: Milk flock of Assaf breed (Awasi x E, Friesian)
Location: Lower Gallilee, Israel.
Indepentent Supervisors: Dr. Reznekov (Sheep Insemination Centre), Nitzan Ziv (Alon Chemicals) and Haim Leibowitz (Charman, Fertility Committee, Ministry of Agriculture).
- The overall treatment protocol was as follows:
Day 0 10-4-88 Implant with Regulin® melatonin implant Day 28 07-5-88 Insert progesterone sponges intravaginally Day 38 17-5-88 Introduce teaser rams Day 41 20-5-88 Remove sponges, inject PM5G (0600 h) Day 43 22-5-88 Inseminate at 50 and 60 h after PMSG injection Day 57 06-6-88 Introductions of rams with markers to look for "returns", continued to Day 64 Day 92 11-7-88 Ultrasound pregnancy check - The treatment groups and results are summarised in the Table 3.
Table 3 Results of Field Trial 4 - Israeli Assaf Sheep: CONCEPTION RATE (%) AI at months post-partum Control + Melatonin Diff(%) 2 58 86 +29 3 60 97 +37 4 87 95 +8 "Trouble"* ewes 45 67 +22 * These ewes had failed to conceive at an earlier AI attempt. - In all treatment groups, supplementary treatment with melatonin led to significant improvement in conception rate.
- In each of the foregoing examples, a variety of agents were used in attempts to improve the reproductive behaviour or efficiency of animals. The mechanisms by which progesterone priming and PMSG treatment exert their effect are well known. Melatonin acts not on the reproductive system directly but on photoperiod perception. Accordingly, it is surprising that supplementary treatment with melatonin-like agents would have any beneficial effect on the actions of the other agents considered here. More surprisingly, we have discovered a greater, synergistic effect, in our experiments as described here.
- Finally, it is to be understood that various other modifications and/or alterations may be made without departing from the spirit of the present invention as outlined herein.
Claims (16)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU4034/87 | 1987-08-28 | ||
AUPI403487 | 1987-08-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0305194A2 true EP0305194A2 (en) | 1989-03-01 |
EP0305194A3 EP0305194A3 (en) | 1990-03-28 |
Family
ID=3772418
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP88307919A Withdrawn EP0305194A3 (en) | 1987-08-28 | 1988-08-26 | Veterinary composition |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP0305194A3 (en) |
IL (1) | IL87574A0 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1097716A1 (en) * | 1999-11-03 | 2001-05-09 | Chronolife Inc. | Dietary anti-adiposity food supplements and drugs based on thyrotropin-releasing hormone (TRH) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988007370A1 (en) * | 1987-03-23 | 1988-10-06 | Applied Medical Research, Ltd. | Compositions and methods of effecting contraception and control of breast cancer |
-
1988
- 1988-08-26 EP EP88307919A patent/EP0305194A3/en not_active Withdrawn
- 1988-08-26 IL IL87574A patent/IL87574A0/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988007370A1 (en) * | 1987-03-23 | 1988-10-06 | Applied Medical Research, Ltd. | Compositions and methods of effecting contraception and control of breast cancer |
Non-Patent Citations (2)
Title |
---|
CHEMICAL ABSTRACTS, vol. 101, 1984, pages 69, abstract no. 841d, Columbus, Ohio, US; A YOKOYAMA; "Reproductive edocrinology in animals" & HORUMON TO RINSHO 1984, 32(4), 323-7 * |
DIALOG, no. 06582666, Medline 88227666; S.L. WALLER et al.: "Effect of melatonin on induction of estrous cycles in anestrous ewes", & J. ANIM. SCI., febr. 1988. 66(2) p459-63 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1097716A1 (en) * | 1999-11-03 | 2001-05-09 | Chronolife Inc. | Dietary anti-adiposity food supplements and drugs based on thyrotropin-releasing hormone (TRH) |
WO2001032195A1 (en) * | 1999-11-03 | 2001-05-10 | Chronolife Inc. | Dietary anti-adiposity food supplements and drugs based on thyrotropin-releasing hormone (trh) |
Also Published As
Publication number | Publication date |
---|---|
EP0305194A3 (en) | 1990-03-28 |
IL87574A0 (en) | 1989-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lopez‐Sebastián et al. | Hormone‐free protocols for the control of reproduction and artificial insemination in goats | |
Pulliam et al. | Safety of ivermectin in target animals | |
EP0246910B1 (en) | Coated veterinary implants | |
Richter et al. | The effect of pimozide/LHRHa and 17α-hydroxyprogesterone on plasma steroid levels and ovulation in the African catfish, Clarias gariepinus | |
WO1996009824A1 (en) | Method for improving reproductive efficiency in farm animals | |
Haresign | The effect of implantation of lowland ewes with melatonin on the time of mating and reproductive performance | |
Kloren et al. | Fleece growth in Australian cashmere goats. III. The seasonal patterns of cashmere and hair growth, and association with growth hormone, prolactin and thyroxine in blood | |
Rowe et al. | Comparison of two sources of gonadotropin for estrus synchronization in does | |
EP0305194A2 (en) | Veterinary composition | |
EP0533818B1 (en) | Process for activating reproduction of seasonal breeding animals by administering l-dihydroxyphenylalanine (l-dopa) | |
Pressing | Pharmacologic control of swine reproduction | |
CA1300501C (en) | Ovulation treatment | |
Ågmo | Mating in male rabbits after anesthesia of the glans penis | |
Ganong et al. | Role of the nervous system in reproductive processes | |
Becker et al. | Gonadotrophin releasing hormone (GnRH) analogs or active immunization against GnRH to control fertility in wildlife | |
CA1294873C (en) | Method of regulating animal reproduction | |
Campbell et al. | Effects of ergot on reproductive performance in mice and gilts | |
UA75089C2 (en) | Method for inducing onset of reproductive cycle of female breeding animals | |
EP0300630A2 (en) | Melatonin for regulating animal reproduction | |
US4751215A (en) | Process for increasing the sexual activity of birds and useful domestic mammals and for preparing spermatozoa suitable to their propagation | |
Stellflug et al. | Influence of exogenous melatonin and altered day length on reproductive performance of Polypay ewes | |
US6844322B2 (en) | Method for induced lactation | |
DE2649914A1 (en) | MEANS TO PROMOTE THE VERTICAL ABILITY OF PETS | |
WO2024117516A1 (en) | Composition for improving reproductive ability of livestock | |
Sebastian et al. | Effects of progesterone pretreatment and duration of ram exposure on synchronization of estrus, conception and pregnancy by prostaglandin during seasonal anestrus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SCHERING AGROCHEMICALS LIMITED |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
RHK1 | Main classification (correction) |
Ipc: A61K 45/06 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE |
|
17P | Request for examination filed |
Effective date: 19900828 |
|
17Q | First examination report despatched |
Effective date: 19910415 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19910827 |